Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02162758 · ClinicalTrials.gov registry record · Phase 2
Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation
A Phase 2 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02162758 is a Phase 2 study that was terminated before completion, run by Takeda. The registered enrollment target is 6 participants.
The verdict
NCT02162758, a Phase 2 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study is designed to evaluate the effect of dexlansoprazole once daily (QD) and twice daily (BID) dosing on the recurrence of intestinal metaplasia (IM) in participants who achieved complete eradication of Barrett's esophagus (BE) with high-grade dysplasia (HGD) following radiofrequency ablation (RFA).
Interventions
- DRUG Dexlansoprazole
- DRUG Dexlansoprazole Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-07 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02162758
The ClinicalTrials.gov registry entry for NCT02162758 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexlansoprazole is the first listed.
NCT02162758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02162758 about?
NCT02162758 is a clinical study titled "Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation". This study is designed to evaluate the effect of dexlansoprazole once daily (QD) and twice daily (BID) dosing on the recurrence of intestinal metaplasia (IM) in participants who achieved complete eradication of Barrett's esophagus (BE) with high-grade dysplasia (HGD) following radiofrequency ablatio...
What is the current status of trial NCT02162758?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2014-07. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02162758?
The interventions under investigation include: Dexlansoprazole (DRUG), Dexlansoprazole Placebo (DRUG).
Who is sponsoring clinical trial NCT02162758?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.